Vemlidy (tenofovir alafenamide) and Viread (Tenofovir disproxil fumarate) are antiviral medications marketed by Gilead Sciences. They are both prodrugs of tenofovir.
Vemlidy and Viread are similar in terms of their effectiveness, but Vemlidy is effective at a much lower dose than Viread. Less tenofovir ends up in the bloodstream after taking Vemlidy, leading to improved renal and bone laboratory safety parameters compared with Viread.
Vemlidy also has greater plasma stability, enabling it to deliver tenofovir to hepatocytes more efficiently.
Vemlidy and Viread are both used to treat chronic hepatitis B virus (HBV) infection, but Viread is also used in the treatment of human immunodeficiency virus-1 (HIV-1) infection.